Indiplon is a non-benzodiazepine hypnotic compound developed for the potential treatment of insomnia, particularly sleep onset insomnia. It acts selectively on the benzodiazepine site of GABA-A receptors in the central nervous system to promote relaxation and facilitate falling asleep faster. With a short half-life, it minimizes next-day residual effects. Indiplon was investigated in clinical trials but has not received regulatory approval for therapeutic use in major markets and is primarily available as a research chemical. It should not be used for self-medication or clinical purposes without appropriate authorization.